Price T Rowe Associates Inc. MD Buys 224,859 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Price T Rowe Associates Inc. MD boosted its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 3.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 6,870,333 shares of the company's stock after acquiring an additional 224,859 shares during the quarter. Price T Rowe Associates Inc. MD owned 10.61% of Kymera Therapeutics worth $276,395,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Wellington Management Group LLP increased its stake in shares of Kymera Therapeutics by 14.9% in the 4th quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company's stock worth $213,514,000 after purchasing an additional 688,967 shares in the last quarter. Avoro Capital Advisors LLC lifted its position in shares of Kymera Therapeutics by 14.4% during the 4th quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company's stock valued at $207,184,000 after buying an additional 650,000 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Kymera Therapeutics by 2.8% during the 4th quarter. Vanguard Group Inc. now owns 4,887,312 shares of the company's stock valued at $196,617,000 after buying an additional 133,546 shares in the last quarter. Geode Capital Management LLC increased its holdings in Kymera Therapeutics by 5.0% in the 4th quarter. Geode Capital Management LLC now owns 1,105,487 shares of the company's stock worth $44,484,000 after acquiring an additional 52,263 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in Kymera Therapeutics by 5.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 387,187 shares of the company's stock worth $15,577,000 after acquiring an additional 20,346 shares in the last quarter.

Kymera Therapeutics Stock Performance

KYMR stock traded down $0.04 during midday trading on Thursday, reaching $34.23. The company's stock had a trading volume of 170,932 shares, compared to its average volume of 554,592. The firm has a market capitalization of $2.22 billion, a price-to-earnings ratio of -14.63 and a beta of 2.22. Kymera Therapeutics, Inc. has a 1 year low of $19.45 and a 1 year high of $53.27. The stock has a fifty day simple moving average of $29.68 and a two-hundred day simple moving average of $38.40.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.12). Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The company had revenue of $7.39 million during the quarter, compared to analysts' expectations of $14.81 million. As a group, analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Ellen Chiniara sold 2,241 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $68,238.45. Following the transaction, the insider now owns 80,085 shares of the company's stock, valued at approximately $2,438,588.25. This represents a 2.72 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Bruce N. Jacobs sold 7,035 shares of Kymera Therapeutics stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $214,215.75. Following the completion of the sale, the chief financial officer now owns 201,886 shares of the company's stock, valued at $6,147,428.70. The trade was a 3.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 10,659 shares of company stock worth $324,567 in the last ninety days. 15.82% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on KYMR shares. Stephens reaffirmed an "overweight" rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Citigroup assumed coverage on shares of Kymera Therapeutics in a research report on Thursday, March 13th. They set a "buy" rating and a $52.00 price objective on the stock. Finally, HC Wainwright upped their target price on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Kymera Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $56.36.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.